102539778
reacted to
Just wanna wish all, especially my fantastic followers and friends ive made here, a fantastic profit filled Friday! A weekly Friday obligation is and does take me away! Besides the profit filled Friday i wish you! I also wish Y’all a safe and great weekend with the ones you love! A small reminder! Mind the charts, if the setup isnt there? Dont enter/trade until it is. As usual if i get time i will check in? But i will definitely check in before 8PM est! To all a great day🤝💵🥂
C...
25
5
102539778
reacted to and commented on
$Knightscope(KSCP.US$ The rampant naked shorting here is awful! I sure hope that the CEO comes out with a answer on what they found / are finding! He hired a outside company to investigate the naked shorting in his company. He knows how bad it is. And how undervalued it has made his company. 🖕🩳’s
Hehehe
1
4
$Knightscope(KSCP.US$ why the beatdown?
1
102539778
reacted to
$Silo Pharma(SILO.US$ For any that caught from my post? A huge congratulations! And if you caught it twice this week from my posts? Well you’re a beast of a trader! WooHoo! Hehehe! Ifn ya get the time and you did trade because of my posts? Could ya hit a button to let me know! Again congrats to all! Y’all that caught made a great decision!🤝💵🥂
9
13
$Immutep(IMMP.US$ waiting and waiting for this to pop
1
102539778
liked
Jim Cramer remains undefeated
Two weeks ago he said “I'd rather buy $General Motors(GM.US$ over $Tesla(TSLA.US$ ” 👇
Since then Tesla has gone up 40% 🚀
Two weeks ago he said “I'd rather buy $General Motors(GM.US$ over $Tesla(TSLA.US$ ” 👇
Since then Tesla has gone up 40% 🚀
3
4
102539778
liked
$Immutep(IMMP.US$ Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearanc...
LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases
• Study expected to enrol first participants during Q3 CY2024
SYDNEY, AUSTRALIA – 17 July 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces it has received regulatory clearanc...
6
2
102539778
liked
$Immutep(IMMP.US$ Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Benzinga· 5 mins ago
Benzinga· 5 mins ago
2
3